Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D03RRJ
|
||||
Former ID |
DNC000803
|
||||
Drug Name |
Iodine-131-tositumomab
|
||||
Drug Type |
Antibody
|
||||
Indication | Discovery agent | Phase 2 | [523216] | ||
Structure |
Download2D MOL |
||||
Formula |
C44H39ClN8O5
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | B-lymphocyte antigen CD20 | Target Info | [535062], [536721] | ||
KEGG Pathway | Hematopoietic cell lineage | ||||
References | |||||
Ref 535062 | A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000 Nov 1;96(9):2934-42. | ||||
Ref 536721 | Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008 Aug 1;112(3):830-5. Epub 2008 May 23. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.